- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03712358
PVSRIPO for Patients With Unresectable Melanoma
A Phase I Trial of PVSRIPO for Patients With Unresectable Melanoma
Study Overview
Detailed Description
The Primary Objective of the study is to determine the safety profile of PVSRIPO in Stage IIIB, IIIC, and IV recurrent melanoma patients as determined by DLTs by cohort, as well as in those retreated with PVSRIPO, when PVSRIPO is injected intralesionally into 1 to 3 or more cutaneous or subcutaneous lesions. As planned, up to 18 patients may be treated with PVSRIPO.
Biopsy material will be obtained from tumor tissue prior to and following virus administration, which may be subjected to routine histology along with molecular genetic testing and evaluation of pathological response. Whole blood for immunologic analyses will also be collected throughout the study period.
Routine study visits will occur through Day 126. Thereafter, visits will occur every 2-3 months for up to 2 years for subjects who do not progress. For patients with progressive disease, chart review only will occur every 3 months starting at the time of progression.
Patients who previously participated in Cohorts 0 through 3, who in the opinion of the investigator, may benefit from continued PVSRIPO administration, may be eligible to receive additional injections.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Undergone prior vaccination against PV and received a boost immunization with trivalent IPOL® (Sanofi-Pasteur SA) at least 1 week, but less than 6 weeks, prior to administration of PVSRIPO (within 6 months of PVSRIPO retreatment).
a. Note: Patients who are unsure of their prior vaccination status/who have not been vaccinated must provide proof of vaccination and/or evidence of anti-PV immunity prior to enrollment, as applicable.
- The patient must have received a boost immunization with trivalent inactivated IPOL™ (Sanofi-Pasteur) at least 1 week prior to administration of the study agent.
- Patient must have histologically proven unresectable, recurrent, melanoma, stage IIIB, IIIC, or stage IV (AJCC staging must be documented in patient's medical record, as determined by CT of the chest, abdomen and pelvis, and/or whole body PET scan, and MRI of the brain within 4 weeks prior to administration of study drug).
- Patients with BRAF mutations, must have failed at least 2 lines of therapy, specifically one BRAF targeted therapy and at least one anti-PD-1 based therapy. For BRAF wild type, patients must have failed at least one anti-PD-1 based therapy.
- Patient must be ≥ 18 years of age.
- Patient must have an ECOG/Zubrod status of 0-1.
- Patient's disease must be bi-dimensionally measurable by caliper or radiological method as defined in the irRC criteria.
At least 1 injectable cutaneous, subcutaneous or nodal melanoma lesion ≥ 10 mm in longest diameter or, multiple injectable melanoma lesions which in aggregate have a longest diameter of ≥ 10 mm (Cohorts 0 and possibly 1). For cohorts where 2 or 3 injections are planned (Cohorts 1 and 2), the patient must have at least 2 injectable melanoma lesions (when 2 doses are planned) or ≥3 injectable melanoma lesions when at least 3 doses are planned in different lesions (Cohorts 2 through 4).
a. Note: PVSRIPO retreatment requires ≥2 lesions amenable to injection.
- At least one measurable lesion that will not be injected.
- Serum lactate dehydrogenase (LDH) levels less than 1.5 x upper limit of normal (ULN).
Patient must have adequate bone marrow, liver and renal function as assessed by the following:
- Hemoglobin > 9.0 g/dl
- White blood count (WBC) of > 2000 m3
- Absolute neutrophil count (ANC) > 1,000/mm3
- Platelet count > 75,000/mm3
- Total bilirubin < 2.0 x ULN
- ALT and AST < 2.5 x the ULN
Exclusion Criteria:
- Females who are pregnant or breast-feeding.
- Adults of reproductive potential not employing an effective method of birth control.
Patients with severe, active co-morbidity, defined as follows:
- Patients with an active infection requiring treatment or having an unexplained febrile illness (Tmax > 99.5°F/37.5°C).
- Patients with impaired cardiac function or clinically significant cardiac disease, such as congestive heart failure requiring treatment (New York Heart Association Class ≥ 2), uncontrolled hypertension or clinically significant arrhythmia; QTcF > 470 msec on ECG if performed or congenital long QT syndrome; acute myocardial infarction or unstable angina pectoris < 3 months prior to study.
- Patients with known lung (FEV1 < 50%) disease or uncontrolled diabetes mellitus (HgbA1c>7).
- Patients with albumin allergy.
- Autoimmune disease: History of or current active autoimmune diseases, [e.g. including but not limited to inflammatory bowel diseases [IBD], rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (such as Guillain-Barre syndrome)]. Vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are not exclusionary.
- Known immunosuppressive disease, human immunodeficiency virus (HIV) infection, or chronic Hepatitis B or C.
- Patients with a previous history of neurological complications due to PV infection.
- Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy. Guidelines for this recovery period are dependent upon the specific therapeutic agent being used. Toxicities must have resolved to CTCAE grade 1 or less with the following exceptions (alopecia, fatigue, vitiligo).
- Patients with undetectable anti-tetanus toxoid IgG.
- Patients with known history of agammaglobulinemia.
- Patients on greater than 10 mg per day of prednisone within the 2 weeks prior to admission for PVSRIPO injection.
- Patients with worsening steroid myopathy (history of gradual progression of bilateral proximal muscle weakness, and atrophy of proximal muscle groups).
- Patients with prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin.
- Clinically active cerebral or bone metastases.
- Greater than 3 visceral metastases (this does not include nodal metastases associated with visceral organs).
- Prior allogeneic stem cell transplantation.
- Concomitant therapy with any of the following: IL-2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses). However, during the course of the study, use of corticosteroids is allowed if used for treating irAEs, adrenal insufficiencies, or if administered at doses of prednisone 10 mg daily or equivalent.
- Active clinically serious infection > CTCAE Grade 2.
- Antineoplastic therapy, radiotherapy, or any other investigational drug within 15 days prior to first study drug administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 0 (PVSRIPO)
A single dose of PVSRIPO into a single lesion.
|
Intralesional injection of PVSRIPO.
|
Experimental: Cohort 1 (PVSRIPO)
A single dose of PVSRIPO into 2 different lesions, 21 days apart, when applicable per dose escalation guidelines.
|
Intralesional injection of PVSRIPO.
|
Experimental: Cohort 2 (PVSRIPO)
A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
|
Intralesional injection of PVSRIPO.
|
Experimental: Cohort 3 (PVSRIPO)
A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
|
Intralesional injection of PVSRIPO.
|
Experimental: Cohort 4 (PVSRIPO)
A single dose of PVSRIPO into a single lesion, followed by PVSRIPO injected into up to 6 lesions at Day 10 and every 21 days thereafter.
|
Intralesional injection of PVSRIPO.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with DLTs by cohort
Time Frame: 24 months
|
To characterize the safety and tolerability of PVSRIPO in AJCC Stage IIIB, IIIC, or IV melanoma.
|
24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rates via measurement of cutaneous lesions every 3 weeks
Time Frame: 24 months
|
To describe the response rates via lesion size of PVSRIPO-injected versus non-injected lesion(s).
|
24 months
|
Number of CD8 positive T cells by IHC on pre treatment and post treatment biopsy (Cohorts 0-3 only)
Time Frame: 4.1 months
|
To describe the number of CD8 positive T cells present in the tumor biopsies before and after injection of PVSRIPO.
|
4.1 months
|
The change in tumor pathology from baseline to after PVSRIPO injection
Time Frame: 4.1 months
|
Determine the pathologic response in tumor biopsies after PVSRIPO by confirming presence or absence of viable tumor cells.
|
4.1 months
|
The detection of viral replication in injected versus non injected lesions (Cohorts 0-3 only)
Time Frame: 4.1 months
|
Determine viral replication via a number of methods (e.g., qRT-PCR, ICH).
|
4.1 months
|
The change in inflammatory cells and markers after PVSRIPO in injected versus non injected lesions (Cohorts 0-3 only)
Time Frame: 4.1 months
|
Determine changes in the tumor microenvironment from biopsies after PVSRIPO; includes but not limited to examination of CD8, PVR (CD155), PD-L1, CD4, FoxPE, and PD-1.
|
4.1 months
|
Change relative to baseline in type and/or function of T cells via flow cytometry (Cohorts 0-3 only)
Time Frame: 24 months
|
Describe how systemic immune cell populations may change after treatment with PVSRIPO.
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Georgia Beasley, MD, Duke University
Publications and helpful links
General Publications
- Beasley GM, Brown MC, Farrow NE, Landa K, Al-Rohil RN, Selim MA, Therien AD, Jung SH, Gao J, Boczkowski D, Holl EK, Salama AKS, Bigner DD, Gromeier M, Nair SK. Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. J Immunother Cancer. 2022 Sep;10(9):e005052. doi: 10.1136/jitc-2022-005052.
- Beasley GM, Nair SK, Farrow NE, Landa K, Selim MA, Wiggs CA, Jung SH, Bigner DD, True Kelly A, Gromeier M, Salama AK. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. J Immunother Cancer. 2021 Apr;9(4):e002203. doi: 10.1136/jitc-2020-002203.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00090774
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
Clinical Trials on PVSRIPO
-
Istari Oncology, Inc.No longer available
-
Istari Oncology, Inc.Duke UniversityActive, not recruiting
-
Istari Oncology, Inc.United States Department of Defense; Duke UniversityCompleted
-
Darell BignerGenentech, Inc.; Istari Oncology, Inc.Withdrawn
-
Istari Oncology, Inc.Duke University; Solving Kids' Cancer; The Andrew McDonough B+ FoundationActive, not recruitingGlioblastoma | Malignant Glioma | Gliosarcoma | Ependymoma | Medulloblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Atypical Teratoid/Rhabdoid Tumor of Brain | Pleomorphic Xanthoastrocytoma of Brain | Embryonal Tumor of BrainUnited States
-
Darell BignerBristol-Myers Squibb; Duke University; Istari Oncology, Inc.Withdrawn
-
Istari Oncology, Inc.National Cancer Institute (NCI); Duke University; Brain Tumor Research Charity...CompletedGlioma | Glioblastoma | Malignant Glioma | GBMUnited States